Ultromics secures FDA breakthrough device designation for cardiac AI

By AuntMinnie.com staff writers

April 27, 2023 -- Ultromics has secured breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its artificial intelligence (AI)-enhanced platform for detecting cardiac amyloidosis.

The platform, EchoGo Amyloidosis, uses AI to analyze echocardiograms and identify the presence of cardiac amyloidosis.

EchoGo Amyloidosis is a module within the company's EchoGo Platform. Ultromics developed it using data from several clinical collaborators and with support from Janssen Biotech, part of the Janssen Pharmaceutical companies of Johnson & Johnson.

Ultromics is preparing regulatory submissions for the platform for the U.S. market and expects that it could be cleared for commercialization in early 2024, it said.


Copyright © 2023 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
What's this?
Sign in using your social networking
account:
(What's this?)


Forgot your password?
|
View our privacy policy.